TY - JOUR
T1 - Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer
AU - Kongsted, Per
AU - Svane, Inge Marie
AU - Lindberg, Henriette
AU - Sengeløv, Lisa
N1 - Copyright © 2016 Elsevier Inc. All rights reserved.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - The present study evaluated treatment outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel in the everyday clinical setting. Medical records from consecutively treated patients were reviewed, and clinical predictors of severe nonhematologic toxicity and febrile neutropenia were identified. Overall survival was inferior to that observed in clinical trials. Older age and dose reductions did not affect the survival outcomes. Background In the present study, we examined possible predictors of chemotherapy-induced toxicity, treatment outcomes, and the consequences of dose reductions in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving standard docetaxel. Patients and Methods Medical records from 421 consecutive patients treated with first-line docetaxel (75 mg/m2 every 3 weeks) and low-dose prednisolone from 2007 to 2013 at Herlev University Hospital were reviewed. Common Terminology Criteria for Adverse Events, version 4.0, and the Prostate Cancer Working Group 2 guidelines were used to evaluate treatment-related toxicity and efficacy. Logistic and Cox regression models were used to predict toxicity and survival. Results Age ≥ 75 years (odds ratio [OR], 2.33), baseline levels of hemoglobin (OR, 0.89), and previous metastatic epidural spinal cord compression (MESCC; OR, 1.70) were predictive of grade 3 and 4 nonhematologic toxicity. Previous MESCC was associated with a greater risk of febrile neutropenia (OR, 2.74). The median progression-free survival (PFS) and overall survival (OS) were 6.4 and 15.4 months, respectively. Survival was similar in the older (age ≥ 75 years) and younger patients (PPFS = .66, POS = .90; log-rank) and when comparing patients undergoing dose reductions with patients treated with standard docetaxel throughout their treatment course (PPFS = .51 and POS = 0.52; log-rank). A longer interval from the primary diagnosis to the initiation of docetaxel (hazard ratio [HR], 1.00), baseline hemoglobin levels (HR, 0.85), Eastern Cooperative Oncology Group performance status > 0 to 1 (HR, 1.44), lactate dehydrogenase greater than the upper limit of normal (HR, 1.64), and prostate-specific antigen levels (HR, 1.00) were predictors of OS. Conclusions OS in the everyday clinical setting was inferior to that observed in randomized trials. Our results indicate that elderly patients and patients with moderate anemia or a history of MESCC at baseline have a greater risk of treatment-induced toxicity. Dose reductions did not compromise survival.
AB - The present study evaluated treatment outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel in the everyday clinical setting. Medical records from consecutively treated patients were reviewed, and clinical predictors of severe nonhematologic toxicity and febrile neutropenia were identified. Overall survival was inferior to that observed in clinical trials. Older age and dose reductions did not affect the survival outcomes. Background In the present study, we examined possible predictors of chemotherapy-induced toxicity, treatment outcomes, and the consequences of dose reductions in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving standard docetaxel. Patients and Methods Medical records from 421 consecutive patients treated with first-line docetaxel (75 mg/m2 every 3 weeks) and low-dose prednisolone from 2007 to 2013 at Herlev University Hospital were reviewed. Common Terminology Criteria for Adverse Events, version 4.0, and the Prostate Cancer Working Group 2 guidelines were used to evaluate treatment-related toxicity and efficacy. Logistic and Cox regression models were used to predict toxicity and survival. Results Age ≥ 75 years (odds ratio [OR], 2.33), baseline levels of hemoglobin (OR, 0.89), and previous metastatic epidural spinal cord compression (MESCC; OR, 1.70) were predictive of grade 3 and 4 nonhematologic toxicity. Previous MESCC was associated with a greater risk of febrile neutropenia (OR, 2.74). The median progression-free survival (PFS) and overall survival (OS) were 6.4 and 15.4 months, respectively. Survival was similar in the older (age ≥ 75 years) and younger patients (PPFS = .66, POS = .90; log-rank) and when comparing patients undergoing dose reductions with patients treated with standard docetaxel throughout their treatment course (PPFS = .51 and POS = 0.52; log-rank). A longer interval from the primary diagnosis to the initiation of docetaxel (hazard ratio [HR], 1.00), baseline hemoglobin levels (HR, 0.85), Eastern Cooperative Oncology Group performance status > 0 to 1 (HR, 1.44), lactate dehydrogenase greater than the upper limit of normal (HR, 1.64), and prostate-specific antigen levels (HR, 1.00) were predictors of OS. Conclusions OS in the everyday clinical setting was inferior to that observed in randomized trials. Our results indicate that elderly patients and patients with moderate anemia or a history of MESCC at baseline have a greater risk of treatment-induced toxicity. Dose reductions did not compromise survival.
KW - Journal Article
U2 - 10.1016/j.clgc.2016.03.018
DO - 10.1016/j.clgc.2016.03.018
M3 - Journal article
C2 - 27102406
SN - 1558-7673
VL - 14
SP - e559-e568
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 6
ER -
